Data Trends provide quick, visually memorable data-driven information and insights that are useful in clinical practice. Here, we explore recent treatment updates in chronic lymphocytic leukemia (CLL) ...

Two patients with chronic lymphocytic leukemia (CLL) can face very different futures. One may live for decades without ...

Leukemias are cancers of the blood cells. Chronic myelogenous leukemia (CML) is an uncommon type of cancer of the bone marrow, which produces blood cells. "Myelogenous" refers to the type of blood ...

This retrospective study evaluates renal safety profiles among patients with chronic myeloid leukemia receiving various first-line tyrosine kinase inhibitor therapies.

Chronic myelomonocytic leukemia (CMML) is a rare type of blood cancer. Some people live a long time with CMML, but others go on to develop acute myeloid leukemia (AML). Chronic myelomonocytic leukemia ...

Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...

<?xml encoding="utf-8" ?> Enliven Therapeutics Inc. ELVN drew an Outperform rating from William Blair on Tuesday as the firm ...

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

B-cell chronic lymphocytic leukemia (CLL) occurs when abnormal B cells accumulate in the bone marrow and blood. This crowds out healthy blood cells and weakens the body’s ability to fight infections.

The chronic phase is the first and most treatable phase of chronic myeloid leukemia. It is characterized by a low percentage of abnormal cells in the blood and bone marrow. With treatment, most people ...

The FDA's approval of pirtobrutinib (Jaypirca) has expanded options for patients with relapsed or refractory CLL/SLL, offering a non-covalent BTK inhibitor that can remain effective even after a ...